1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Duodenal Ulcer – Pipeline Review, H1 2013

Duodenal Ulcer – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 35 pages

Duodenal Ulcer – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Duodenal Ulcer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Duodenal Ulcer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Duodenal Ulcer. Duodenal Ulcer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Duodenal Ulcer.
- A review of the Duodenal Ulcer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Duodenal Ulcer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Duodenal Ulcer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Duodenal Ulcer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Duodenal Ulcer - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Duodenal Ulcer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Duodenal Ulcer 7
Duodenal Ulcer Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Duodenal Ulcer Therapeutics - Products under Development by Companies 13
Companies Involved in Duodenal Ulcer Therapeutics Development 14
Takeda Pharmaceutical Company Limited 14
Eisai Inc. 15
Sihuan Pharmaceutical Holdings Group Ltd. 16
Duodenal Ulcer - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
vonoprazan - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
rabeprazole sodium - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Anaprazole - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Duodenal Ulcer Therapeutics - Drug Profile Updates 27
Duodenal Ulcer Therapeutics - Dormant Products 29
Duodenal Ulcer - Product Development Milestones 30
Featured News and Press Releases 30
Jun 22, 2012: AstraZeneca Receives Approval For Nexium In Japan For Prevention Of Recurrence Of Gastric ulcer And Duodenal Ulcer 30
Mar 29, 2012: Covis's Zantac Injection Returns To Market 30
Dec 05, 2011: Horizon Pharma Launches DUEXIS 800mg/26.6mg In US 31
Oct 24, 2011: Daiichi Sankyo And AstraZeneca Apply For Additional Indication In Japan For NEXIUM 10mg And 20mg Capsules 32
Sep 16, 2011: Takeda's TAK-438 Enters Into Phase III Clinical Trials In Japan For Treatment Of Acid-Related Diseases 32
Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers 33
Jan 30, 2009: Santarus Submits New Drug Application For ZEGERID Tablet Product 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35



List of Tables

Number of Products Under Development for Duodenal Ulcer, H1 2013 7
Products under Development for Duodenal Ulcer - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Late Stage Development, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Takeda Pharmaceutical Company Limited, H1 2013 14
Eisai Inc., H1 2013 15
Sihuan Pharmaceutical Holdings Group Ltd., H1 2013 16
Assessment by Monotherapy Products, H1 2013 17
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Stage and Molecule Type, H1 2013 21
Duodenal Ulcer Therapeutics - Drug Profile Updates 27
Duodenal Ulcer Therapeutics - Dormant Products 29



List of Figures

Number of Products under Development for Duodenal Ulcer, H1 2013 7
Products under Development for Duodenal Ulcer - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 17
Assessment by Route of Administration, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Molecule Type, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H2 2016

Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog ...

Interleukin 15 (IL15) - Pipeline Review, H2 2016

Interleukin 15 (IL15) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 15 (IL15) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 15 (IL15) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 15 (IL15) targeted ...

Interleukin 13 (IL13) - Pipeline Review, H2 2016

Interleukin 13 (IL13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Interleukin 13 (IL13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 13 (IL13) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 13 (IL13) targeted ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.